Site Editors

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Advertisement
Advertisement

Recent News

NTRK3 Fusion–Positive Sarcoma: 6-Year-Old Girl Treated With Larotrectinib and Radiotherapy
ASCO 2022: Update on Use of Entrectinib for Advanced NTRK Fusion–Positive Solid Tumors
ASCO 2022: Health-Related Quality of Life With Larotrectinib for TRK-Fusion Cancer
FDA Brief: Companion Diagnostic for Entrectinib Receives Approval
ASCO 2022: Expanded Cohort Update on Larotrectinib for NTRK Fusion–Positive Lung Cancer
ASCO 2022: How Common Are NTRK Alterations in Colorectal Cancer?
NTRK Fusion–Positive NSCLC: Challenges in Detection Methods
Tyrosine Kinase Inhibitor Under Study in CNS Tumors With NTRK, ROS1, or ALK Fusions
A Tale of Two TRK Inhibitors: Comparison of Entrectinib and Larotrectinib
Use of Pan-TRK Immunohistochemistry to Identify NTRK/TRK Mutations in a Dutch Population
How NTRK Genes Function in NSCLC May Offer Clues to Appropriate Therapeutic Strategies
South Korean Study on Detection of NTRK Fusions Using Next-Generation Sequencing
Molecular Lesions in NTRK Receptors: Focus on Breast Cancers
AACR 2022: New Fuzzion2 Program Identifies Common Gene Fusions in Cancer
AACR 2022: Is Response to Larotrectinib Influenced by NTRK Gene Fusion Variability?
AACR 2022: Case of Acquired TPM3-NTRK1 Fusion Resistant to Therapy in Lung Cancer
Molecular Investigation of High-Grade Gliomas in Children
Larotrectinib in NTRK Fusion–Positive Thyroid Cancer: Real-World Case Series
Are NTRK Fusions Found in Both Secretory and Nonsecretory Breast Cancers?
Morphologic Characterization of Mesenchymal Tumors With NTRK Alterations
Shedding Light on the Role of NTRK Gene Fusions in Cancer
MAPK Signaling and CIC-Mediated Modulation in NTRK Fusion Sarcomas
Identification of NTRK Fusions in Solid Tumors: Focus on Local Testing Approaches
How RET/NTRK Fusion Mutations May Impact Outcomes in Pediatric Thyroid Cancer
NTRK and RET Fusion–Positive Thyroid Cancers: Identify and Treat Early
Long-Term Survival Predictions Among Patients With Solid Tumors That Harbor NTRK Fusions
Larotrectinib in TRK Fusion–Positive Primary CNS Cancer
Pan-TRK Immunodetection of NTRK Fusions in Atypical Melanocytic Tumors
Gastrointestinal Malignancies: Biomarker Analysis Via Immunohistochemistry
Comparing Next-Generation Sequencing Assays: Which Is Best for NTRK Fusion Detection?
Spotlight

JNCCN Spotlights

View More
Advertisement

Resources

For Cancer Care

View More
Sections
360 Hub
NCCN Resources
Copyright© 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.